Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
Figure 1
Role of CTLA-4 in T-cell responses and the impact of CTLA-4 blockade with ipilimumab. (a) Two signals are required for activation of T-cells. (b) Upon activation, CTLA-4 is upregulated, and once bound to the costimulatory molecule it prevents further immune activation. (c) Ipilimumab binds CTLA-4 thus augmenting T-cell response.